Arbutus Biopharma Corporation
ABUS
$2.98
$0.093.11%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.44% | 3.94% | -17.61% | -4.62% | 25.50% |
| Total Depreciation and Amortization | -1.11% | -2.71% | 7.89% | 2.40% | 8.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 522.99% | -86.95% | 11.36% | 15.32% | -7.40% |
| Change in Net Operating Assets | -292.27% | 143.97% | 15.53% | 67.54% | -451.00% |
| Cash from Operations | -11.58% | 20.62% | -11.38% | 28.36% | -60.69% |
| Capital Expenditure | -- | 100.00% | 96.27% | -634.19% | 12.69% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.96% | 112.86% | 353.96% | -86.31% | 30.84% |
| Cash from Investing | -47.38% | 113.11% | 623.73% | -91.36% | 31.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 541.71% | 126.47% | -64.55% | -76.77% | 84.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 541.71% | 126.47% | -64.55% | -76.77% | 84.20% |
| Foreign Exchange rate Adjustments | -192.86% | 75.00% | 900.00% | -125.00% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.10% | 190.56% | 27.74% | -236.53% | 44.68% |
